Heparin octadecasaccharides influence iduronate-2-sulphatase activity in a mutation-dependent manner in Mucopolysaccharidosis type II
Life Sciences, Medicine and Biomedicine · 18.03.2026 · 10 (1)
DOI: 10.28916/lsmb.10.1.2026.239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Sciences, Medicine and Biomedicine, online erschienen am 18.03.2026. Verfasst von Affandi Omar und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a lysosomal storage disorder caused by deficiency of iduronate-2-sulphatase (IDS), resulting in glycosaminoglycans (GAG) accumulation and progressive multi-system pathology. Enzyme replacement therapy improves somatic manifestations but has limited neurological benefit. Therefore, pharmacological chaperone therapy has been proposed as a mutation-dependent strategy to stabilise misfolded IDS variants with residual activity. This study evaluated the effect of heparin octadecasaccharides (HO18) in patient-derived fibroblasts representing five genotypes and in HEK293T cells expressing IDS mutants. HO18 treatment (15 µM, 96 hours) produced mutation-specific effects across both experimental systems, with GAG reduction observed only in selected IDS variants. In fibroblasts carrying the p.Ile360Arg variant, IDS activity increased by approximately 1.8-fold along with a marked reduction in GAG levels (~71%). Other genotypes showed partial responses, including increased IDS activity without significant GAG reduction or GAG reduction in the absence of detectable IDS activity enhancement. In recombinant systems, HO18 increased IDS activity in p.Asn63Asp (~1.2-fold) and reduced GAG accumulation in p.Asn63Asp and p.Leu314Pro variants, while catalytically inactive mutants showed no response. Overall, HO18 exhibited pharmacological chaperone-like effects in selected IDS variants but also produced mutation-specific outcomes not fully explained by IDS activity enhancement alone. These findings support further in vitro investigation of HO18 as a mutation-dependent small-molecule approach for IDS-related pathology, while highlighting the need to better understand how HO18 acts and to confirm its effects in in vivo models.
Zitieren
APA
Omar, A., Rahman, S. A., Nordin, F. D. A., Aziz, N. A., Erham, S. A. M., Kamarudin, B., Mohamed, R., Khalid, M. K. N. M., Muhamad, N. J., Ngu, L. H., Leong, H. Y., Jalil, J. A., & Noorden, M. S. A. (2026). Heparin octadecasaccharides influence iduronate-2-sulphatase activity in a mutation-dependent manner in Mucopolysaccharidosis type II. Life Sciences, Medicine and Biomedicine, 10(1). https://doi.org/10.28916/lsmb.10.1.2026.239
Vancouver
Omar A, Rahman SA, Nordin FDA, Aziz NA, Erham SAM, Kamarudin B, et al. Heparin octadecasaccharides influence iduronate-2-sulphatase activity in a mutation-dependent manner in Mucopolysaccharidosis type II. Life Sciences, Medicine and Biomedicine. 2026;10(1). doi:10.28916/lsmb.10.1.2026.239
BibTeX
@article{Omar2026,
author = {Omar, Affandi and Rahman, Salina Abdul and Nordin, Fatimah Diana Amin and Aziz, Nur Azian and Erham, Siti Aishah Mohd and Kamarudin, Balqis and Mohamed, Rosnani and Khalid, Mohd Khairul Nizam Mohd and Muhamad, Nur Jannaim and Ngu, Lock Hock and Leong, Huey Yin and Jalil, Julaina Abdul and Noorden, Mohd Shihabuddin Ahmad},
title = {Heparin octadecasaccharides influence iduronate-2-sulphatase activity in a mutation-dependent manner in Mucopolysaccharidosis type II},
journal = {Life Sciences, Medicine and Biomedicine},
year = {2026},
volume = {10},
number = {1},
doi = {10.28916/lsmb.10.1.2026.239}
}
EUVIMED